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Key Points
• Subsequent solid
cancers after HCT
occurred at younger
ages than primary
cancers and accounted
for most common
causes of deaths.
• Subsequent solid can-
cers after HCT showed
similar or worse survival
compared with primary
cancers in the general
population.
To characterize the outcomes of patients who developed a particular subsequent solid
cancer after hematopoietic cell transplantation (HCT), age at cancer diagnosis, survival,
and causes of death were compared with the respective primary cancer in the general
population, using data from the national HCT registry and population-based cancer
registries in Japan. Among 31 867 patients who underwent a ﬁrst HCT between 1990 and
2013 and had progression-free survival at 1 year, 713 patients developed subsequent solid
cancer. The median age at subsequent solid cancer diagnosis was 55 years, which was
signiﬁcantly younger than the 67 years for primary cancer patients in the general
population (P , .001). The overall survival probability was 60% at 3 years after diagnosis
of subsequent solid cancer and differed according to cancer type. Development of most
solid cancers was associated with an increased risk of subsequent mortality after HCT.
Subsequent solid cancers accounted for 76% of causes of death. Overall survival
probabilities adjusted for age, sex, and year of diagnosis were lower in the HCT population
than in the general population for colon, bone/soft tissue, and central nervous system
cancers and did not differ statistically for other cancers. In conclusion, most subsequent
solid cancers occurred at younger ages than primary cancers, emphasizing the need for
cancer screening at younger ages. Subsequent solid cancers showed similar or worse
survival compared with primary cancers. Biological and genetic differences between
primary and subsequent solid cancers remain to be determined.
Introduction
Hematopoietic cell transplantation (HCT) is a curative treatment of a variety of hematologic diseases.
Mortality associated with HCT has declined over the past several decades.1 As a result, the number of
HCT survivors is growing,2 with a current estimate of one half million worldwide, and survivors are at
considerable risk for many late effects.3 Development of subsequent solid cancer is one of the most
debilitating late effects after HCT and accounts for 12% to 27% of deaths among long-term survivors.4-6
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The cumulative incidence of subsequent solid cancer has been
reported to be 1% to 6% at 10 years after HCT, and it continues to
rise over time without a plateau.7-11 The most common sites include
the oral cavity, skin, breast, and thyroid, and risks of solid cancer are
elevated in the esophagus, liver, central nervous system, bone, and
connective tissues in post-HCT patients compared with the general
population.7-11 Notably, subsequent cancers in digestive organs such
as the esophagus and colon are frequent in Japanese patients.10,12
Myeloablative total body irradiation (TBI), young age at HCT, chronic
graft-versus-host disease (GVHD), and prolonged treatment with
immunosuppressive medications are well-documented risk factors for
the development of subsequent solid cancer.11
Although many studies have reported an increased incidence of
subsequent solid cancer after HCT as well as associated risk
factors, there are limited studies on the outcomes of patients
who developed a specific subsequent solid cancer. One study
examined the outcomes of 112 patients who developed sub-
sequent solid cancer before 1995 after allogeneic HCT using the
Center for International Blood and Marrow Transplant Research
(CIBMTR) registry. The 5-year overall survival probabilities after
the diagnosis of subsequent solid cancer varied by cancer type,
being ;90% for thyroid, testis, and melanoma; ;50% for breast,
oral cavity/pharynx, soft tissue, and female reproductive organs;
and #20% for bone, lower gastrointestinal tract, and central
nervous system.13 Although a formal statistical comparison was
not performed, these probabilities seemed similar to those for
primary cancers in the general population but were lower for
female reproductive organs, bone, lower gastrointestinal tract, and
central nervous system.
To characterize the outcomes of individual subsequent solid
cancers after HCT in a contemporary cohort, we analyzed a
large data set from the national HCT registry and population-
based cancer registries in Japan. The aims of this study were
to (1) elucidate overall survival rates and causes of death
after the diagnosis of individual subsequent solid cancers, (2)
examine the association between the development of differ-
ent solid cancers and the risk of subsequent mortality after
HCT, (3) examine factors associated with overall mortality, and
(4) compare age at cancer diagnosis and survival between
patients with subsequent cancer in the HCT population and
those with primary cancer in the general population. The results of
this study will provide physicians with important information for
counseling and managing patients who develop subsequent solid
cancers after HCT.
Patients and methods
Data source
HCT data were collected through the Transplant Registry Unified
Management Program sponsored by the Japan Society for Hemato-
poietic Stem Cell Transplantation and the Japanese Data Center
for Hematopoietic Cell Transplantation.14,15 More than 99% of all
transplant centers in Japan reported and updated outcomes every
year.14 Cancer survival data in the general population were collected
from the population-based cancer registries through the Monitoring of
Cancer Incidence in Japan project conducted by the Japan Cancer
Surveillance Research Group.16 Registries that met the following
criteria were considered high quality and were used for the study: (1)
the proportion of patients for whom the death certificate provided the
only notification to the registry was,25% or the proportion of patients
for whom the death certificate provided the first notification to the
registry was,30%, and (2) the mortality:incidence ratio was,0.67.16
The following 21 registries were included and encompassed 41% of
the total Japanese population: Miyagi, Yamagata, Fukushima, Ibaraki,
Tochigi, Gunma, Kanagawa, Fukui, Yamanashi, Aichi, Shiga, Osaka,
Hyogo, Hiroshima, Kochi, Nagasaki, and Okinawa.16
The study cohort included all patients who underwent a first
autologous or allogeneic HCT between 1990 and 2013 and whose
progression-free survival was at least 1 year after HCT. Patients
with Fanconi anemia, primary immunodeficiency diseases, or Down
syndrome were excluded because of their inherent susceptibility to
cancer. Patients with a history of solid cancer before HCT were
also excluded. For comparison with primary cancer patients in the
general population, patients from the population-based cancer
registries who had the same age range and cancer type were used.
This study was approved by the institutional review board of the
National Cancer Center and was conducted in accordance with the
Declaration of Helsinki.
Definitions
Cancer type was classified according to International Classifica-
tion of Diseases, 10th revision. HLA matching for sibling and cord
blood transplantation was assessed by serological data for the
HLA-A, -B, and -DR loci. HLA matching for unrelated trans-
plantation was assessed by using allele data for the HLA-A, -B, -C,
and -DRB1 loci.15 HLA mismatch was defined in the GVHD vector
when recipient antigens were not shared by the donor. The
intensity of conditioning regimens was defined as described
previously.17
Statistical analysis
Continuous variables were compared using the Mann-Whitney
U test. The probability of overall survival was estimated by the
Kaplan-Meier method from the diagnosis of solid cancer to death
or last follow-up. Separate Cox models were used for autolo-
gous and allogeneic HCT to examine risk factors associated
with overall mortality after the diagnosis of solid cancer. Factors
with P, .05 in univariable testing were entered in a multivariable
model. A backward stepwise procedure was used to develop a
final model. A 2-sided P , .05 was considered statistically
significant. Covariates included patient age at diagnosis of solid
cancer, duration from HCT to diagnosis of solid cancer, patient
sex, type of solid cancer, year of solid cancer diagnosis, primary
disease requiring HCT, prior history of HCT, graft source, and
the use of TBI in conditioning regimen. Donor relation, HLA
matching, conditioning intensity, and a history of chronic GVHD
were also included as covariates for patients who had allogeneic
HCT. The proportional hazards assumption was tested for all
variables considered in multivariable analysis, and no violations
occurred. The 3-year survival was compared between the HCT
and general population after adjustment for patient sex, patient
age at cancer diagnosis, year of cancer diagnosis, and cancer
type. The standardized mortality ratio (SMR) was calculated as
the ratio of observed deaths to expected deaths in the age- and
sex-matched general population of primary cancer, and 95%
confidence intervals (CIs) were obtained using a Poisson
regression model.18 All statistical analyses were performed
using STATA version 12.1 (StataCorp, College Station, TX).
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Results
Patient characteristics
Among 31 867 patients (10 678 autologous HCT and 21 189
allogeneic HCT) who underwent a first HCT and had progression-
free survival at 1 year after HCT, 713 progression-free patients
(2%) developed subsequent solid cancer. Solid cancer
occurred after autologous HCT in 217 patients (30%) and
after allogeneic HCT in 496 patients (70%). The median patient
age at diagnosis of solid cancer was 55 years (range, 5-82
years). The median duration from HCT to solid cancer diagnosis
was 5.9 years (range, 1.0-25 years). The duration from HCT
to solid cancer diagnosis according to cancer type is shown
in Figure 1. Four hundred forty-nine patients (63%) were male
and 264 (37%) were female. The most frequent cancer was
oropharyngeal cancer (n 5 117), followed by cancers of the
esophagus (n 5 83), lung (n 5 81), colon (n 5 79), and
stomach (n 5 48). The most frequent primary disease was
malignant lymphoma (n 5 227), followed by acute myeloid
leukemia (n 5 171) and acute lymphoblastic leukemia (n 5
101). Other characteristics are summarized in Table 1. When
characteristics were compared between autologous and
allogeneic HCT, patients after allogeneic HCT were younger
at cancer diagnosis, had a longer duration from HCT to cancer
diagnosis, more frequently had oropharyngeal or esophageal
cancer, less frequently had colon or lung cancer, less frequently
had prior HCT, more frequently had bone marrow transplantation
using TBI-containing conditioning regimens for leukemia or myeloid
neoplasms, and less frequently had lymphoma or plasma cell
neoplasms.
Survival and causes of death after diagnosis of
subsequent solid cancer
With a median follow-up duration of 2.6 years among survivors,
the unadjusted overall survival probabilities at 3 years after the
diagnosis of solid cancer were 60% (95% CI, 52% to 67%) for
autologous HCT and 61% (95% CI, 56% to 66%) for allogeneic
HCT and did not differ statistically between the two HCT types
(P 5 .35; Figure 2). Multivariable Cox models for autologous
HCT showed that female patients were associated with a lower
risk of overall mortality (hazard ratio [HR], 0.59; 95% CI, 0.36-
0.97; P 5 .039), and solid cancer diagnosis before 2000 was
associated with a higher risk of overall mortality (HR, 2.45; 95%
CI, 1.14-5.26; P 5 .022) (Table 2). Multivariable Cox models
for allogeneic HCT showed 2 factors associated with overall
mortality (Table 2). A longer duration from HCT to diagnosis of
solid cancer was associated with a lower risk of overall mortality
(HR, 0.94; 95% CI, 0.91-0.98; P 5 .005). Compared with
oropharyngeal cancer, cancers of the esophagus, pancreas,
lung, and central nervous system were associated with higher
risks of overall mortality, while thyroid cancer was associated
with a lower risk of overall mortality. Age at diagnosis of solid
cancer, primary disease, graft source, the use of TBI in condition-
ing regimen, donor relation, HLA matching, conditioning intensity,
and a history of chronic GVHD were not statistically associated
with the risk of overall mortality.
Regarding causes of death, subsequent solid cancer accounted
for 73% of causes of death in patients who had autologous HCT
and 76% of causes of death in those who had allogeneic HCT
(Figure 3). Analysis in individual cancers showed that subsequent
solid cancer was the most common cause of death, except for
cancers of the esophagus, breast, and bladder after autologous
HCT (Figure 3A), and except for liver and breast cancers after
allogeneic HCT (Figure 3B).
Association of subsequent solid cancer development
with risk of subsequent overall mortality in
HCT patients
Time-varying Cox models were used to examine the association
of solid cancer development with risk of subsequent overall
mortality in the 31 867 patients with 1-year progression-
free survival. Results are shown with unadjusted models and
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Figure 1. Duration from HCT to solid cancer diagnosis
according to cancer type. Data are mean + standard error of
the mean (SEM).
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Table 1. Characteristics of patients at diagnosis of subsequent solid cancer
Characteristic
Total (N 5 713), Autologous (N 5 217), Allogeneic (N 5 496),
P*no. (%) no. (%) no. (%)
Median age at diagnosis of solid cancer (range), y 55 (5-82) 62 (10-82) 52 (5-76) ,.001
Median duration from HCT to diagnosis of solid cancer (range), y 5.9 (1.0-25) 4.9 (1.0-20) 6.3 (1.0-25) ,.001
Patient sex .37
Male 449 (63) 142 (65) 307 (62)
Female 264 (37) 75 (35) 189 (38)
Cancer type (ICD-10 code) ,.001
Oral cavity/pharynx (C00-C14) 117 (16) 8 (4) 109 (22)
Esophagus (C15) 83 (12) 7 (3) 76 (15)
Stomach (C16) 48 (7) 20 (9) 28 (6)
Colon (C18-C20) 79 (11) 36 (17) 43 (9)
Liver (C22) 20 (3) 14 (6) 6 (1)
Pancreas (C25) 25 (4) 10 (5) 15 (3)
Lung (C33-C34) 81 (11) 38 (18) 43 (9)
Bone/soft tissue† (C40-C41) 31 (4) 9 (4) 22 (4)
Skin (C43-C44) 28 (4) 4 (2) 24 (5)
Breast (C50) 38 (5) 14 (6) 24 (5)
Cervix uteri (C53) 9 (1) 1 (,1) 8 (2)
Corpus uteri (C54) 13 (2) 4 (2) 9 (2)
Prostate (C61) 22 (3) 12 (6) 10 (2)
Kidney (C64-C65) 15 (2) 10 (5) 5 (1)
Bladder (C67) 19 (3) 7 (3) 12 (2)
Central nervous system (C71-72) 16 (2) 2 (1) 14 (3)
Thyroid (C73) 28 (4) 6 (3) 22 (4)
Other‡ 41 (6) 15 (7) 26 (5)
Year of diagnosis of solid cancer .12
1993-1999 18 (3) 9 (4) 9 (2)
2000-2004 88 (12) 31 (14) 57 (11)
2005-2009 203 (28) 52 (24) 151 (30)
2010-2015 404 (57) 125 (58) 279 (56)
Primary disease ,.001
Acute myeloid leukemia 171 (24) 20 (9) 151 (30)
Acute lymphoblastic leukemia 101 (14) 7 (3) 94 (19)
Myelodysplastic syndrome/myeloproliferative neoplasms 77 (11) 1 (,1) 76 (15)
Chronic myelogenous leukemia 60 (8) 0 (0) 60 (12)
Malignant lymphoma 227 (32) 160 (74) 67 (14)
Plasma cell neoplasms 34 (5) 29 (13) 5 (1)
Adult T-cell leukemia/lymphoma 20 (3) 0 (0) 20 (4)
Aplastic anemia 21 (3) 0 (0) 21 (4)
Other 2 (,1) 0 (0) 2 (,1)
Prior history of HCT 27 (4) 13 (6) 14 (3) .04
Graft source ,.001
Bone marrow 352 (49) 12 (6) 340 (69)
Mobilized blood cells 313 (44) 205 (94) 108 (22)
Cord blood 48 (7) 0 (0) 48 (10)
ICD-10, International Classification of Diseases, 10th revision.
*P values for autologous vs allogeneic HCT.
†Includes soft tissue cancers defined as ICD-O3 880-892, 912, and 918-926.
‡Nine patients had bile duct cancer, 8 cancer of unknown origin, 6 malignant peripheral nerve sheath tumor, 6 duodenum cancer, 4 ovarian cancer, 3 parotid gland cancer, 3 ureter cancer, 1
laryngeal cancer, and 1 submandibular gland cancer.
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with models adjusted for factors associated with the risk of
subsequent solid cancer development in prior studies (ie,
patient age at HCT, prior chronic GVHD, and the use of TBI in
conditioning regimen).10 Development of any solid cancer was
associated with an increased risk of subsequent overall mortality
after autologous HCT (adjusted HR, 3.81; 95% CI, 3.05-4.75;
P , .001) and after allogeneic HCT (adjusted HR, 5.63; 95%
CI, 4.81-6.59; P , .001). Analyses for individual cancers are
shown in Figure 4. Compared with patients who did not develop
subsequent solid cancer, those who developed solid cancer
had an increased risk of subsequent overall mortality, except
for those with cancers of the oral cavity/pharynx, central
nervous system, breast, thyroid, bladder, and kidney after
autologous HCT and except for those with cancers of the
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Figure 2. Probability of overall survival after diagnosis of
subsequent solid cancer according to HCT type.
Table 1. (continued)
Characteristic
Total (N 5 713), Autologous (N 5 217), Allogeneic (N 5 496),
P*no. (%) no. (%) no. (%)
TBI in conditioning regimen 324 (45) 21 (10) 303 (61) ,.001
Donor relation
Related 271 (55)
Unrelated 225 (45)
HLA matching
Match 299 (60)
Mismatch 143 (29)
Unknown 54 (11)
Conditioning intensity
Myeloablative 245 (49)
Reduced intensity 146 (29)
Unknown intensity 105 (21)
Chronic GVHD
None 410 (58)
Limited 110 (15)
Extensive 193 (27)
ICD-10, International Classification of Diseases, 10th revision.
*P values for autologous vs allogeneic HCT.
†Includes soft tissue cancers defined as ICD-O3 880-892, 912, and 918-926.
‡Nine patients had bile duct cancer, 8 cancer of unknown origin, 6 malignant peripheral nerve sheath tumor, 6 duodenum cancer, 4 ovarian cancer, 3 parotid gland cancer, 3 ureter cancer, 1
laryngeal cancer, and 1 submandibular gland cancer.
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kidney, uterus, prostate, bladder, thyroid, and breast after
allogeneic HCT.
Comparison of age at diagnosis among patients with
primary vs subsequent solid cancer
The ages at diagnosis of cancers were compared between
patients with subsequent solid cancer after HCT and those with
primary cancer in the general population with the same age
range and cancer type by using data from the population-based
cancer registries (Table 3). The median age at diagnosis of all
solid cancers combined was significantly younger in the HCT
population than in the general population (62 vs 67 years after
autologous HCT, P , .001; 52 vs 67 years after allogeneic
HCT, P , .001). This observation held true for lung and bladder
cancers after autologous HCT and for cancers except for
breast, uterus, prostate, and bladder after allogeneic HCT. The
age at cancer diagnosis was younger after allogeneic HCT than
after autologous HCT for cancers of the oral cavity/pharynx,
esophagus, colon, liver, lung, skin, and thyroid.
Comparison of adjusted survival probabilities
between patients with primary vs subsequent
solid cancer
Overall survival probabilities adjusted for age, sex, and year of
diagnosis were compared between patients with subsequent solid
cancer after HCT and those with primary cancer in the general
population, using the same data from the population-based cancer
registries (Table 4). The adjusted overall survival probability was lower
in the HCT population than in the general population in all cancers
combined after allogeneic HCT (60% vs 72% at 3 years; HR, 1.41;
95% CI, 1.20-1.65; P , .001). Results for individual cancers are
shown in Table 4 and Figure 5. The adjusted overall survival
probabilities were lower in the HCT population than in the general
population for bone/soft tissue cancer after autologous HCT
(21% vs 67% at 3 years; HR, 2.93; 95% CI, 1.21-7.07; P5 .017);
and for colon cancer (54% vs 75% at 3 years; HR, 2.14; 95% CI,
1.27-3.62; P 5 .004), bone/soft tissue cancer (24% vs 67% at
3 years; HR, 3.16; 95% CI, 1.68-5.93; P , .001), and central
Table 2. Multivariable analysis for factors associated with overall mortality after diagnosis of subsequent solid cancer
Factor
Autologous (N 5 217) Allogeneic (N 5 496)
No. Hazard ratio (95% CI) P No. Hazard ratio (95% CI) P
Patient sex
Male 142 1.00 (reference)
Female 75 0.59 (0.36-0.97) .039
Year of diagnosis of solid cancer
1993-1999 9 2.45 (1.14-5.26) .022
2000-2004 31 0.79 (0.42-1.49) .47
2005-2009 52 0.80 (0.46-1.39) .44
2010-2015 125 1.00 (reference)
Duration from transplantation to cancer diagnosis (per year) 496 0.94 (0.91-0.98) .005
Cancer type
Oral cavity/pharynx 109 1.00 (reference)
Esophagus 76 2.43 (1.52-3.90) ,.001
Stomach 28 1.06 (0.48-2.34) .89
Colon 43 1.35 (0.74-2.45) .32
Liver 6 3.01 (0.92-9.90) .069
Pancreas 15 6.78 (3.29-14.0) ,.001
Lung 43 2.54 (1.45-4.46) .001
Bone/soft tissue 22 1.82 (0.91-3.65) .093
Skin 24 0.69 (0.27-1.78) .44
Breast 24 0.14 (0.02-1.05) .056
Cervix uteri 8 0.84 (0.20-3.55) .82
Corpus uteri 9 0.43 (0.06-3.13) .40
Prostate 10 0.69 (0.16-2.89) .61
Kidney 5 0.92 (0.12-6.71) .93
Bladder 12 0.63 (0.15-2.63) .52
Central nervous system 14 4.12 (2.01-8.45) ,.001
Thyroid 22 0.12 (0.02-0.87) .036
Others 26 2.21 (1.13-4.33) .021
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nervous system cancer after allogeneic HCT (1% vs 27% at 3 years;
HR, 4.54; 95%CI, 2.29-9.01;P, .001). The adjusted overall survival
probabilities did not differ statistically between primary and sub-
sequent solid cancers for other cancers.
Compared with the age- and sex-matched general population of
primary cancers (Table 5), SMRs of subsequent solid cancers were
elevated after both autologous and allogeneic HCT in all cancers
combined (1.79; 95% CI, 1.43-2.21; P , .001; 1.66; 95% CI, 1.43-
1.93; P, .001, respectively), colon cancer (2.20; 95% CI, 1.17-3.77;
P5 .02; 2.12; 95% CI, 1.26-3.35; P5 .007, respectively), and bone/
soft tissue cancer (3.16; 95% CI, 1.16-6.87; P5 .03; and 2.97; 95%
CI, 1.48-5.32; P5 .003, respectively). The SMR after autologous HCT
was elevated for breast cancer (5.00; 95% CI, 1.62-11.7; P 5 .01).
Discussion
This registry study elucidated different overall survival probabili-
ties according to types of subsequent solid cancers after HCT.
Importantly, development of most solid cancers was associated
with an increased risk of subsequent mortality, and solid cancer was
the most common cause of death, with few exceptions. This study
also demonstrated that many subsequent solid cancers after HCT
occurred at younger ages and were associated with comparable or
worse survival compared with the same type of primary cancers in
the general population, emphasizing the need for cancer screening
at younger ages in HCT survivors.
It was shown that subsequent cancers of the skin and colon that
developed after organ transplantation occurred at a younger age
than primary cancer in the general population.19-21 A plausible
explanation for the early carcinogenesis after organ transplantation
is that immunosuppressive conditions can impair the cancer
surveillance mechanism.22 Immunosuppressive conditions may also
increase the risk of viral reactivation and virus-related malignancies.23
Chronic mucosal inflammation caused by chronic GVHDmay increase
the risk of carcinogenesis after allogeneic HCT. In fact, cancer de-
velopment at a younger age was particularly evident after allogeneic
HCT. Thus, cumulative chemotherapy-induced DNA damage, pro-
longed immunosuppressive conditions, and chronic mucosal inflam-
mation, particularly after allogeneic HCT, could account for the younger
age of cancer development after HCT.
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Figure 3. Causes of death among patients who de-
veloped subsequent solid cancer after HCT. (A) Autolo-
gous HCT. Skin and prostate cancers are excluded because
no death occurred with these cancers. (B) Allogeneic HCT.
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Previous studies have reported 3-year overall survival probabilities
of 50% to 60% after diagnosis of subsequent solid cancer,13,24,25
and the probability was similar in this study. In analyses of individual
cancers, adjusted overall survival probabilities were favorable for
thyroid, breast, prostate, and skin cancers, whereas they were poor
for bone/soft tissue, central nervous system, and pancreatic
cancers. These results were consistent with those reported in the
study of the CIBMTR registry.13
Adjusted overall survival probabilities were lower in patients with
subsequent cancer compared with those with primary cancer in the
general population for colon, central nervous system, and bone/soft
tissue cancers after allogeneic HCT. The CIBMTR registry study
also reported worse survival probabilities in subsequent cancers of
the lower gastrointestinal tract, central nervous system, and bones
and joints after allogeneic HCT.13 Although these results require
careful interpretation because of the lack of information on cancer
stage at diagnosis and treatment details in both registries,
similarities between the 2 independent registry studies might
indicate the presence of biological differences between primary and
subsequent cancers. A recent population-based study showed that
subsequent cancers of the breast, thyroid, soft tissues, colon,
central nervous system, and cervix were associated with worse
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Figure 4. Association of individual solid cancer development
with risk of subsequent overall mortality. Diagnosis of individ-
ual solid cancer was treated as time-varying mutually exclusive
events. Patients who did not develop subsequent solid cancer were
used as reference. Hazard ratios and 95% confidence intervals are
shown with forest plots in unadjusted (blue) and adjusted (red)
models. (A) Autologous HCT. Adjusted factors include patient age
at transplantation and the use of TBI. Skin and prostate cancers
are excluded because no deaths occurred with these cancers.
(B) Allogeneic HCT. Adjusted factors include patient age at trans-
plantation, prior chronic GVHD, and the use of TBI.
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survival than primary cancers.26 Many subsequent cancers that
occurred after organ transplantation were characterized by aggres-
sive behavior.27 Several studies showed that subsequent colorectal
cancer after organ transplantation had a more aggressive phenotype
and worse prognosis compared with primary cancer in the general
population, possibly because of immunosuppression.19,20,28 Several
population-based studies also showed that cancer histology differed
between subsequent and primary cancer, and that the risk of death was
higher with subsequent cancer despite increased surveillance, screen-
ing, and access to care among previous cancer patients.29,30 Additional
studies are necessary to elucidate biological and genetic differences
between primary cancers and subsequent cancers after HCT.
Table 4. Comparison of adjusted overall survival probabilities with primary cancer patients in the general population
Cancer type
No. 3-y adjusted overall survival* Autologous vs general Allogeneic vs general
General Autologous Allogeneic General Autologous Allogeneic HR* (95% CI) P HR* (95% CI) P
All 541 134 217 496 0.72 0.65 0.60 1.21 (0.96-1.53) .11 1.41 (1.20-1.65) ,.001
Oral cavity/pharynx 7 904 8 109 0.65 0.85 0.62 0.55 (0.08-3.93) .56 0.99 (0.65-1.49) .95
Esophagus 13 804 7 76 0.42 0.47 0.34 0.61 (0.15-2.44) .48 1.15 (0.83-1.60) .40
Stomach 82 076 20 28 0.66 0.54 0.57 1.61 (0.76-3.37) .21 1.37 (0.65-2.87) .41
Colon 72 270 36 43 0.75 0.63 0.54 1.57 (0.85-2.92) .15 2.14 (1.27-3.62) .004
Liver 32 078 14 6 0.45 0.47 0.44 0.95 (0.43-2.12) .91 1.32 (0.42-4.10) .63
Pancreas 11 329 10 15 0.12 0.20 0.07 0.81 (0.34-1.95) .64 1.24 (0.67-2.31) .49
Lung 63 833 38 43 0.38 0.42 0.28 0.88 (0.55-1.42) .60 1.12 (0.73-1.72) .61
Bone/soft tissue 2 404 9 22 0.67 0.21 0.24 2.93 (1.21-7.07) .017 3.16 (1.68-5.93) ,.001
Skin 5 582 4 24 0.88 NA 0.92 NA NA 0.60 (0.08-4.27) .61
Breast 50 155 14 24 0.93 0.91 0.90 1.35 (0.19-9.57) .77 0.99 (0.14-7.07) 1.0
Cervix uteri 6 459 1 8 0.81 NA 0.61 NA NA 2.71 (0.67-10.9) .16
Corpus uteri 7 298 4 9 0.87 NA 0.86 NA NA 1.59 (0.22-11.5) .65
Prostate 18 481 12 10 0.91 1.00 0.81 NA NA 3.26 (0.46-23.2) .24
Kidney 9 051 10 5 0.76 0.83 0.22 0.63 (0.09-4.51) .65 2.27 (0.32-16.1) .41
Bladder 6 959 7 12 0.78 1.00 0.72 NA NA 0.74 (0.10-5.27) .76
Central nervous system 750 2 14 0.27 NA 0.01 NA NA 4.54 (2.29-9.01) ,.001
Thyroid 9 507 6 22 0.97 0.94 0.84 2.01 (0.27-14.8) .49 4.47 (0.63-31.9) .14
NA, not applicable.
*Adjusted for patient sex, patient age at cancer diagnosis, year of cancer diagnosis, and cancer type. Hazard ratios and P values were derived from multivariable Cox models.
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Figure 5. Age-, sex-, and year of diagnosis–adjusted
overall survival probability at 3 years after diagnosis
of subsequent solid cancer in the HCT population and
primary cancer in the general population. Cancers in the
skin, uterus, and central nervous system after autologous
HCT are excluded because of the small number of patients.
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Multivariable analysis showed that female patients and cancer
diagnosis before 2000 were associated with overall mortality after
autologous HCT, and a longer duration from HCT to diagnosis of
solid cancer was associated with a lower risk of overall mortality after
allogeneic HCT. Patient age at diagnosis of solid cancer, type of
HCT, primary disease, conditioning intensity, and the use of TBI in
conditioning regimen were not statistically associated with the risk of
overall mortality. Female cancer patients showed higher survival
probabilities than male cancer patients in the study of population-
based cancer registries.16 Because patients are likely to recover
physically and because mortality rates decrease with time after HCT,
it would not be surprising if later development of solid cancer were
associated with lower mortality. The CIBMTR study, however, did not
show a decrease in mortality associated with longer duration between
HCT and subsequent cancer diagnosis after allogeneic HCT.13
This study had several strengths and limitations. We used a national
HCT registry and population-based cancer databases in Japan,
and thus the results could be generalized to all HCT survivors
nationwide. Conversely, the major drawback of the current HCT
registry database was the lack of information on subsequent cancer
stage at diagnosis, treatment details, health behaviors, or cytoge-
netic features. Collection of these details is warranted in future
studies to determine whether adverse outcomes were related to
advanced stage as a result of late diagnosis, intolerability to
standard treatment, aggressive behaviors, or combinations of these
factors. Finally, the results for some cancers were based on a small
number of cases and should be interpreted with caution.
This registry study clearly showed that subsequent solid cancer was
associated with an increased risk of mortality and accounted for the
major cause of death in most cancers. Outcomes differed largely
according to cancer type. These results should prove useful when
counseling and managing patients who develop subsequent solid
cancers after HCT. Because many of these cancers occurred at a
younger age than primary cancers in the general population, our
results highlight the importance of cancer screening at younger
ages among HCT survivors and will help to make evidence-based
prevention and screening guidelines for HCT survivors. Additional
studies are warranted to characterize the biological and genetic
differences of subsequent solid cancers after HCT.
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Table 5. Expected and observed deaths according to cancer type
Cancer type
Autologous Allogeneic
Expected* Observed SMR (95% CI) P Expected* Observed SMR (95% CI) P
All 47.0 84 1.79 (1.43-2.21) ,.001 107.6 179 1.66 (1.43-1.93) ,.001
Oral cavity/pharynx 2.3 2 0.87 (0.11-3.14) 1.0 24.7 31 1.26 (0.85-1.78) .25
Esophagus 1.8 2 1.11 (0.13-4.01) 1.0 38.8 40 1.03 (0.74-1.40) .89
Stomach 3.6 8 2.22 (0.96-4.38) .16 5.7 8 1.40 (0.61-2.77) .43
Colon 5.9 13 2.20 (1.17-3.77) .02 8.5 18 2.12 (1.26-3.35) .007
Liver 7.1 8 1.13 (0.49-2.22) .83 3.4 3 0.88 (0.18-2.58) 1.0
Pancreas 5.0 5 1.00 (0.32-2.33) 1.0 9.8 10 1.02 (0.49-1.88) 1.0
Lung 18.7 17 0.91 (0.53-1.46) .81 18.8 21 1.12 (0.69-1.71) .67
Bone/soft tissue 1.9 6 3.16 (1.16-6.87) .03 3.7 11 2.97 (1.48-5.32) .003
Skin NA 0 NA NA 2.7 5 1.85 (0.60-4.32) .27
Breast 1.0 5 5.00 (1.62-11.7) .01 1.5 1 0.67 (0.02-3.71) 1.0
Cervix uteri NA 1 NA NA 0.7 2 2.86 (0.35-10.3) .31
Corpus uteri NA 3 NA NA 0.6 1 1.67 (0.04-9.29) 1.0
Prostate 0.6 0 NA NA 0.6 2 3.33 (0.40-12.0) .24
Kidney 1.5 1 0.67 (0.02-3.71) 1.0 0.5 1 2.00 (0.05-11.1) .79
Bladder 1.2 1 0.83 (0.02-4.64) 1.0 1.2 2 1.67 (0.20-6.02) .68
Central nervous system NA 1 NA NA 7.1 10 1.41 (0.68-2.59) .35
Thyroid 0.2 1 5.00 (0.13-27.9) .36 0.4 1 2.50 (0.06-13.9) .66
*Expected number of deaths in the age- and sex-matched general population of primary cancer.
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